IL-17A Softens the Skin: Antifibrotic Properties of IL-17A in Systemic Sclerosis
- PMID: 31864428
- DOI: 10.1016/j.jid.2019.07.678
IL-17A Softens the Skin: Antifibrotic Properties of IL-17A in Systemic Sclerosis
Abstract
IL-17A is abundant in scleroderma skin, but its pathologic role has remained unclear. In the Journal of Investigative Dermatology, Dufour et al. (2020) demonstrate a new role for IL-17A as an antifibrotic agent in scleroderma through modulation of keratinocyte responses to transforming growth factor-β and shifting of fibroblast responses from profibrotic to antifibrotic.
Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved.
Comment on
-
IL-17A Dissociates Inflammation from Fibrogenesis in Systemic Sclerosis.J Invest Dermatol. 2020 Jan;140(1):103-112.e8. doi: 10.1016/j.jid.2019.05.026. Epub 2019 Jul 3. J Invest Dermatol. 2020. PMID: 31276679
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
